Abstract
We investigated the association of the Finnish Diabetes Risk Score (FINDRISC) with insulin secretion, insulin sensitivity, and risk of type 2 diabetes, drug-treated hypertension, cardiovascular (CVD) events and total mortality in a follow-up study of the Metabolic Syndrome in Men (METSIM) cohort. The METSIM study includes 10,197 Finnish men, aged 45–73 years, and examined in 2005–2010. Of 8,749 non-diabetic participants of the METSIM study 693 developed incident type 2 diabetes, 225 started antihypertensive medication, 351 had a CVD event, and 392 died during a 8.2-year follow-up. The FINDRISC was significantly associated with decreases in insulin secretion and insulin sensitivity (P<0.0001), and with a 4.14-fold increased risk of incident type 2 diabetes, 2.43-fold increased risk of drug-treated hypertension, 1.61-fold increased risk of CVD, and 1.55-increased risk of total mortality (the FINDRISC ≥12 vs. < 12 points). In conclusion, the FINDRISC predicts impairment in insulin secretion and insulin sensitivity, the conversion to type 2 diabetes, drug-treated hypertension, CVD events and total mortality.
Highlights
Detection of individuals at high risk of the development of type 2 diabetes is of great importance [1,2,3]
In our follow-up study of the large population-based Metabolic Syndrome in Men (METSIM) cohort we evaluated the associations of the FINDRISC with changes in insulin secretion, insulin sensitivity, insulin resistance related traits and the risk of type 2 diabetes, drug-treated hypertension, CVD events, and total mortality
We hypothesized that the FINDRISC is likely to be a marker of impaired insulin secretion since insulin secretion defect is needed for the conversion to diabetes
Summary
Detection of individuals at high risk of the development of type 2 diabetes is of great importance [1,2,3]. A variety of risk scores has been developed and applied either in the cross-sectional [4] or prospective setting to evaluate the risk of diabetes [5,6]. These risk scores include conventional risk factors for diabetes, including age, body mass index (BMI), information on diet and family history [6,7], laboratory measurements [8,9] and/or genetic information [10,11]. No potential conflicts of interest relevant to this article are reported
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
